基于实际体重的高剂量羟氯喹与SLE flare风险降低相关且耐受性维持
本研究纳入182例SLE患者,按实际体重(ABW)分为羟氯喹≥5 mg/kg(高剂量组)与<5 mg/kg(低剂量组),采用逆概率治疗加权调整背景。高剂量组与低剂量组5年因不良事件停药率无显著差异,但高剂量组3年无flare率数值更高,且每增加0.2 mg/kg羟氯喹剂量flare风险降低(HR 0.91,95%CI 0.84-0.99)。
要点
- 基于ABW的羟氯喹高剂量(≥5 mg/kg)与低剂量组因不良事件停药率无显著差异。
- 高剂量组3年无flare率数值上高于低剂量组,但差异未达统计学显著。
- 每增加0.2 mg/kg羟氯喹剂量,flare风险降低(HR 0.91,95%CI 0.84-0.99)。
核心结论
- 高剂量与低剂量羟氯喹在疗效和安全性上未观察到明确差异,但较高羟氯喹剂量与flare风险降低相关。
- 较低羟氯喹剂量可能与SLE患者flare风险升高相关,提示基于实际体重给药的重要性。
研究设计与样本
- 回顾性队列研究,纳入182例SLE患者,按实际体重(ABW)分为羟氯喹≥5 mg/kg(高剂量组)与<5 mg/kg(低剂量组)。
- 采用逆概率治疗加权(IPTW)方法调整患者背景,评估总体队列(组1)因不良事件停药率。
- 在病程≥1年(组2)及羟氯喹起始后未加用其他免疫抑制剂和生物制剂(组3)的亚组中比较flare率、泼尼松剂量和血清学数据。
主要发现
- 组2中高剂量组与低剂量组3年无flare率分别为75.0%和60.7%(P=0.239)。
- 组3中高剂量组与低剂量组3年无flare率分别为79.2%和57.8%(P=0.141)。
- 组3中羟氯喹剂量每增加0.2 mg/kg,flare风险降低(HR 0.91;95%CI 0.84-0.99)。
关键数值与推荐
- 高剂量定义为羟氯喹剂量≥5 mg/kg实际体重,低剂量定义为<5 mg/kg实际体重。
- 组3中羟氯喹剂量每增加0.2 mg/kg,flare风险的HR为0.91(95%CI 0.84-0.99)。
临床怎么用
- 对于SLE患者,可考虑基于实际体重计算羟氯喹剂量,较高剂量(≥5 mg/kg)可能有助于降低flare风险且耐受性可接受。
- 在决定羟氯喹剂量时,应结合患者实际体重评估flare风险与不良事件风险。
局限性
- 高剂量组与低剂量组在flare率比较中差异未达统计学显著(P=0.239和P=0.141),结果需谨慎解读。
- 本研究为单中心回顾性研究,样本量有限(182例),结论需更大规模前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The effects of HCQ dose based on actual body weight (ABW) on SLE remain unclear. We investigated the effects of HCQ dose based on ABW of patients with SLE. METHODS: Patients were classified into ≥5 mg/kg ABW [high dose (HD)] and <5 mg/kg ABW [low dose (LD)] groups. Patient backgrounds were adjusted using inverse probability of treatment weighting method. The discontinuation rate owing to adverse events of overall cohort (group 1) was evaluated. Subgroups with a disease duration ≥1 year (group 2) and without additional immunosuppressive agents and biologics after HCQ initiation (group 3) were compared with evaluated flare rates, prednisolone dose and serological data. RESULTS: Among 182 patients in group 1, 60 (33%) comprised the HD group. Five-year discontinuation rates were 18.9% and 13.6% in the HD and LD groups, respectively (P = 0.314). Three-year flare-free rates in HD group were higher than those in LD group: 75.0% (HD) vs 60.7% (LD) (P = 0.239) in group 2, and 79.2% (HD) vs 57.8% (LD) (P = 0.141) in group 3. In group 3, each 0.2 mg/kg increase in the HCQ dose reduced flares (hazard ratio 0.91; 95% CI 0.84-0.99). CONCLUSION: No clear differences in efficacy and safety were observed between the HD and LD groups; however, a higher HCQ dose was associated with a reduced flare risk. Our findings suggest that a lower HCQ dose may be associated with a higher flare risk in patients with SLE, highlighting the importance of HCQ dose based on ABW.
引用
- Yamamoto S, Sato T, Nagatani K, et al. Higher hydroxychloroquine dose based on actual body weight is associated with lower SLE flare risks while maintaining tolerability. Rheumatology (Oxford). 2026. PMID: 42104096. doi:10.1093/rheumatology/keag242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。